# US 6,730,698 B2 · Method and compositions for administering taxanes orally to human patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,698 B2
- Document ID: US6730698B2
- Status: Granted
- Kind: B2
- Application number: 10/072,398
- Filed: 2002-02-06
- Published: 2002-10-24
- Granted: 2004-05-04
- Earliest claimed: 1995-10-26
- Assignees: Baker Norton Pharmaceuticals, Inc.
- Inventors: Samuel Broder; Kenneth L. Duchin; Sami Selim
- Web page: https://patentgrep.com/patent/US6730698B2

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 38/13: Cyclosporins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

## Claims

### Claim 1

A method of making an orally administrable taxane bioavailable to human patients at a level sufficient to treat taxane-responsive disease conditions, comprising orally co-administering to said patient a taxane comprising a derivative, an analog or a prodrug of paclitaxel or docetaxel, and an oral bioavailability enhancing agent comprising a cyclosporin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the taxane comprises a derivative, an analog or a prodrug of paclitaxel.

### Claim 3 (depends on 1)

The method of claim 1 wherein the taxane comprises a derivative, an analog or a prodrug of docetaxel.

### Claim 4 (depends on 1)

The method of claim 1 wherein about 0.1 to about 20 mg/kg of the enhancing agent is co-administered based on patient body weight.

### Claim 5 (depends on 1)

The method of claim 1 wherein about 5 mg/kg of the enhancing agent is co-administered based on patient body weight.

### Claim 6 (depends on 1)

The method of claim 1 wherein the taxane is co-administered in an amount of from about 2-30 mg/kg based on patient body weight.

### Claim 7 (depends on 6)

The method of claim 6 wherein the amount is from about 2-6 mg/kg.

### Claim 8 (depends on 1)

The method of claim 1 wherein the taxane is co-administered in an amount of from about 20-1000 mg/m2 based on patient body surface area.

### Claim 9 (depends on 8)

The method of claim 8 wherein the amount is from about 50-200 mg/m2.

### Claim 10 (depends on 1)

The method of claim 1 wherein the taxane is a derivative, an analog or a prodrug of paclitaxel and the enhancing agent is cyclosporin A.

### Claim 11 (depends on 10)

The method of claim 10 wherein about 2-30 mg/kg or about 20-1,000 mg/m2 of paclitaxel and about 0.1-20 mg/kg of cyclosporin A are co-administered to the patient.

### Claim 12 (depends on 1)

The method of claim 1 wherein the enhancing agent is administered either (a) about 0.5-72 hours before, (b) less than 0.5 hours before, together with or less than 0.5 hours after, or (c) both about 0.5-72 hours before and again less than 0.5 hours before, together with or less than 0.5 hours after the administration of the taxane.

### Claim 13 (depends on 1)

The method of claim 1 wherein the taxane and the enhancing agent are co-administered in separate oral dosage forms.

### Claim 14 (depends on 1)

The method of claim 1 wherein the taxane and the enhancing agent are co-administered together in a combination oral dosage form.

### Claim 15 (depends on 1)

The method of claim 1 wherein the disease condition is selected from the group consisting of cancers, tumors, malignancies, uncontrolled tissue or cellular proliferation secondary to tissue injury, polycystic kidney disease and malaria.

### Claim 16 (depends on 1)

The method of claim 1 wherein the disease condition is a cancer selected from the group consisting of hepatocellular carcinoma, liver metastases, cancers of the gastrointestinal tract, pancreas, prostate and lung and Kaposi's sarcoma.

### Claim 17 (depends on 1)

The method of claim 1 wherein said cyclosporin is selected from the group consisting of cyclosporins A through Z, (Me-lle-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A and related oligopeptides produced by species in the genus Tolypocladium.

### Claim 18 (depends on 1)

The method of claim 1 wherein said cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.

### Claim 19

A method of preventing or reducing hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, comprising orally co-administering to the patient a taxane and an oral bioavailability enhancing agent, without prior administration of medication to prevent the hypersensitivity or allergic reactions, wherein the taxane reaches therapeutic blood or plasma levels in said patient.

### Claim 20 (depends on 19)

The method of claim 19, wherein the taxane is selected from the group consisting of paclitaxel and analogs, derivatives and prodrugs thereof.

### Claim 21 (depends on 19)

The method of claim 19 wherein the taxane is a analog of paclitaxel.

### Claim 22 (depends on 21)

The method of claim 21, wherein the analog of paclitaxel is docetaxel.

### Claim 23 (depends on 19)

The method of claim 19, wherein the enhancing agent is administered either
a) about 0.5-72 hrs. before,
b) less than 0.5 hr. before, together with or less than 0.5 hr. after, or
c) both about 0.5-72 hrs. before and again less than 0.5 hr. before, together with or less than 0.5 hr. after, the administration of the taxane.

### Claim 24 (depends on 19)

The method of claim 19, wherein the taxane and the enhancing agent are administered in separate oral dosage forms.

### Claim 25 (depends on 19)

The method of claim 19, wherein the taxane and the enhancing agent are administered together in a combination oral dosage form.

### Claim 26 (depends on 19, 23)

The method of claim 19 or claim 23, wherein the taxane is paclitaxel.

### Claim 27 (depends on 26)

The method of claim 26, wherein the enhancing agent is cyclosporin A.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cyclosporin A is administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.

### Claim 29 (depends on 28)

The method of claim 28, wherein the paclitaxel and the cyclosporin A are orally co-administered once a week.

### Claim 30 (depends on 29)

The method of claim 29, wherein the paclitaxel is administered in a divided dose.

### Claim 31 (depends on 19, 23)

The method of claim 19 or claim 23 wherein the taxane is docetaxel.

### Claim 32 (depends on 31)

The method of claim 31, wherein the enhancing agent is cyclosporin A.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cyclosporin A is administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.

### Claim 34 (depends on 19)

The method of claim 19 wherein two or more doses of the taxane are administered after a single dose of the enhancing agent.

### Claim 35 (depends on 19)

The method of claim 19, wherein the patient is administered about 20-1,000 mg/m2 of the taxane based on patient body surface area.

### Claim 36 (depends on 35)

The method of claim 35, wherein the patient is administered about 50-200 mg/m2 of the taxane.

### Claim 37 (depends on 19)

The method of claim 19, wherein the taxane comprises about 2-30 mg/kg of paclitaxel based on patient body weight.

### Claim 38 (depends on 37)

The method of claim 37, wherein the taxane comprises about 2-6 mg/kg of paclitaxel.

### Claim 39 (depends on 19)

The method of claim 19, wherein the patient is administered about 0.1 to about 20 mg/kg of the enhancing agent based on patient body weight.

### Claim 40 (depends on 19)

The method of claim 19, wherein the taxane, the enhancing agent or both is each administered in a dosage form selected from the group consisting of tablets, softgel capsules, hardgel capsules, caplets, gelcaps, pills, lozenges, powders, micronized particles, osmotic delivery systems, and liquid solutions, suspensions and elixirs.

### Claim 41 (depends on 19)

The method of claim 19, wherein the taxane administered is paclitaxel in a formulation further comprising a polyethoxylated castor oil, alcohol or polyoxyethylated sorbitan mono-oleate.

### Claim 42 (depends on 19)

The method of claim 19, wherein the disease condition is a cancer, tumor, malignancy, uncontrolled tissue or cellular proliferation secondary to tissue injury, or an inflammatory disease.

### Claim 43 (depends on 19)

The method of claim 19, wherein the disease condition is selected from the group consisting of pancreatic cancer, prostate cancer, hepatocellular carcinoma, liver metastases, genito-urinary and gasrointestinal tract cancers, Kaposi's sarcoma, polycystic kidney disease and malaria.

### Claim 44 (depends on 19)

The method of claim 19, wherein the disease condition is selected from the group consisting of gastrointestinal tract cancers and lung cancers.

### Claim 45 (depends on 19)

The method of claim 19, wherein the disease condition is cancer.

### Claim 46 (depends on 45)

The method of claim 45, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosnourin A.

### Claim 47 (depends on 46)

The method of claim 46, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patients.

### Claim 48 (depends on 47)

The method of claim 47, wherein the paclitaxel and the cyclosporin A are orally co-administered about once per week.

### Claim 49 (depends on 48)

The method of claim 48, wherein the paclitaxel is administered in a divided dose.

### Claim 50 (depends on 45)

The method of claim 45, wherein the taxane is docetaxel.

### Claim 51 (depends on 50)

The method of claim 50, wherein the bioavailability enhancing agent is cyclosporin A.

### Claim 52 (depends on 51)

The method of claim 51, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 53 (depends on 19)

The method of claim 19, wherein the disease condition is lung cancer.

### Claim 54 (depends on 53)

The method of claim 53, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

### Claim 55 (depends on 54)

The method of claim 54, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 56 (depends on 55)

The method of claim 55, wherein the paclitaxel and the cyclosporin A are orally co-administered about once per week.

### Claim 57 (depends on 56)

The method of claim 56, wherein the paclitaxel is administered in a divided dose.

### Claim 58 (depends on 53)

The method of claim 53, wherein the taxane is docetaxel.

### Claim 59 (depends on 58)

The method of claim 58, wherein the bioavailability enhancing agent is cyclosporin A.

### Claim 60 (depends on 59)

The method of claim 59, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 61 (depends on 19)

The method of claim 19, wherein the disease condition is a cancer of the gastrointestinal tract.

### Claim 62 (depends on 61)

The method of claim 61, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

### Claim 63 (depends on 62)

The method of claim 62, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 64 (depends on 63)

The method of claim 63, wherein the paclitaxel and the cyclosporin A are orally co-administered about once per week.

### Claim 65 (depends on 64)

The method of claim 64, wherein the paclitaxel is administered in a divided dose.

### Claim 66 (depends on 61)

The method of claim 61, wherein the taxane is docetaxel.

### Claim 67 (depends on 66)

The method of claim 66, wherein the bioavailability enhancing agent is cyclosporin A.

### Claim 68 (depends on 67)

The method of claim 67, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 69 (depends on 19)

The method of claim 19 wherein the taxane is a derivative, an analog of a prodrug of paclitaxel or docetaxel.

### Claim 70 (depends on 19)

The method of claim 19 wherein the taxane is paclitaxel 2′-MPM or docetaxel 2′-MPM.

### Claim 71 (depends on 19)

The method of claim 19 wherein the bioavailability enhancing agent is a cyclosporin.

### Claim 72 (depends on 71)

The method of claim 71, wherein the cyclosporin is selected from the group consisting of cyclosporins A though Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A, and related oligopeptides produced by species of the genus Tolypocladium.

### Claim 73 (depends on 71)

The method of claim 71, wherein the cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.

### Claim 74 (depends on 71)

The method of claim 71, wherein the cyclosporin is cyclosporin A.

### Claim 75 (depends on 19)

The method of claim 19, further comprising a subsequent administration of the taxane without co-administration of the bioavailability enhancing agent.

### Claim 76 (depends on 27)

The method of claim 27, further comprising a subsequent administration of the paclitaxel without co-administration of the cyclosporin A.

### Claim 77 (depends on 19)

The method of claim 19, wherein the disease condition is ovarian cancer.

### Claim 78 (depends on 77)

The method of claim 77, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

### Claim 79 (depends on 78)

The method of claim 78, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 80 (depends on 79)

The method of claim 79, wherein the paclitaxel and the cyclosporin A are orally co-administered about once per week.

### Claim 81 (depends on 80)

The method of claim 80, wherein the paclitaxel is administered in a divided dose.

### Claim 82 (depends on 77)

The method of claim 77, wherein the taxane is docetaxel.

### Claim 83 (depends on 82)

The method of claim 82, wherein the bioavailability enhancing agent is cyclosporin A.

### Claim 84 (depends on 83)

The method of claim 83, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 85 (depends on 19)

The method of claim 19, wherein the disease condition is breast cancer.

### Claim 86 (depends on 85)

The method of claim 85, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

### Claim 87 (depends on 86)

The method of claim 86, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.

### Claim 88 (depends on 87)

The method of claim 87, wherein the paclitaxel and the cyclosporin A are orally co-administered about once per week.

### Claim 89 (depends on 88)

The method of claim 88, wherein the paclitaxel is administered in a divided dose.

### Claim 90 (depends on 85)

The method of claim 85, wherein the taxane is docetaxel.

### Claim 91 (depends on 90)

The method of claim 90, wherein the bioavailability enhancing agent is cyclosphorin A.

### Claim 92 (depends on 91)

The method of claim 91, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are orally administered to the patient.
